In vitro activity of tigecycline against ampicillin-resistant Haemophilus influenzae isolates [1]

Journal of Antimicrobial Chemotherapy

Volumn 55, Issue 5, 2005, Pages 809-810

  Betriu, C ^a   Gomez M ^a   Rodriguez Avial I ^a   Culebras, E ^a   Picazo, J J ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Antimicrobial susceptibility; Glycylcyclines; Respiratory infections

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; BETA LACTAMASE; CHLORAMPHENICOL; COTRIMOXAZOLE; TETRACYCLINE; TIGECYCLINE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CONTROLLED STUDY; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SEROTYPE;

AMPICILLIN RESISTANCE; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; RESPIRATORY TRACT INFECTIONS;

EID: 18844409485     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki096     Document Type: Letter

References (7)

1. Fritsche, T. R., Kirby, J. T. & Jones, R. N. (2004). In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections. Diagnostic Microbiology and Infectious Diseases 49, 201-9.
2. Zhanel, G. G., Palatnick, L., Nichol, K. A. et al. (2003). Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrobial Agents and Chemotherapy 47, 1875-81.
3. Picazo, J. J., Betriu, C., Rodríguez-Avial, I. et al. (2002). Vigilancia de resistencias a los antimicrobianos: estudio VIRA, Enfermedades Infecciosas y Microbiologia Clinica 20, 503-10.
4. Picazo, J. J., Betriu, C., Rodríguez Avial, I. et al. (2004). Vigilancia de resistencias a los antimicrobianos: estudio VIRA 2004. Enfermedades Infecciosas y Microbiologia Clinica 22, 517-25.
5. National Committee for Clinical Laboratory Standards. (2003). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: Approved Standard M7-A6. NCCLS, Wayne, PA, USA.
6. Lefort, A., Lafaurie, M., Massias, L. et al. (2003). Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrobial Agents and Chemotherapy 47, 216-22.
7. Muralidharan, G., Getsy, J., Mayer, P., et al. (1999). Pharmacokinetics (PK), safety and tolerability of GAR-936, a novel glycylcycline antibiotic, in healthy subjects. In Program and Abstracts of the Thirty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Abstract 416, p. 303. American Society for Microbiology, Washington, DC, USA.